Scientific and Practical Conference
“The VI Moscow International School of Young Scientists in Hematology named after S. P. Botkin”
February 27–28, 2026
Venue: Novotel Moscow City Hotel, 2 Presnenskaya Embankment, Moscow
online broadcast at https://med-conferences.ru/vi_mihs
February 27th, 2026
08:00–18:50
| FEBRUARY 27th, 2026 | ||
|---|---|---|
| Timing | Title | Speakers |
| 07:15-16:00 | REGISTRATION | |
| 08:00-08:15 | Opening ceremony of VI Moscow International School of Young Scientists in Hematology named after S.P. Botkin | Introductory remarks: Prof. Kulagin A.D., Prof. Nikitin E.A., Prof. Ptushkin V.V. |
| 08:15-09:35 | TRANSPLANTATION. Session Chairs: Prof. Alexandr Kulagin, Prof. Vadim Ptushkin | |
| 08:15-08:30 | Comparison of Two GVHD Prophylaxis Platforms in Pediatric Allogeneic HSCT | Anna Vlasova, Regional Children's Clinical Hospital, Yekaterinburg, Russia |
| 08:30-08:45 | Autologous Stem Cell Transplantation Outcomes after Anti-PD-1 Treatment in Third and Subsequent Lines for Relapsed/Refractory Classical Hodgkin Lymphoma | Yulia Protopopova, Pirogov National Medical Surgical Center, Moscow, Russia |
| 08:45-09:00 | Predictors of hepatic veno-occlusive disease in children with acute leukemia after allogeneic hematopoietic stem cell transplantation following antibody-drug conjugate therapy | Zhemal Rakhmanova, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 09:00-09:15 | Optimization of Infection Prevention in Patients with Lymphoproliferative Diseases After Auto-HSCT Using Intravenous Immunoglobulin | Olga Gerasimovich, Minsk Scientific and Practical Center of Surgery, Transplantology and Hematology, Minsk, Republic of Belarus |
| 09:15-09:30 | Maribavir for treatment of refractory/recurrent cytomegalovirus infection in allogeneic HSCT recipients | Aleksandr Sinyaev, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 09:30-09:35 | Discussion | |
| 09:35-10:55 | LYMPHOPROLIFERATIVE DISORDERS AND PLASMA CELL DISCRASIAS (PART 1). Session Chairs: Prof. Gayane Tumyan, Prof. Elena Baryakh, Dr. Lali Babicheva | |
| 09:35-09:50 | PET-Adapted Omission of Salvage Chemotherapy in Responders to Second-Line Nivolumab Monotherapy for Hodgkin Lymphoma (NCT04981899) | Polina Kotseliabina, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 09:50-10:05 | First-line immunochemotherapy for primary central nervous system lymphoma: Russian multicenter study | Vladislav Markelov, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 10:05-10.20 | The first experience with a new PD-1 inhibitor (prolgolimab) in the treatment of patients with relapsed/refractory classical Hodgkin's lymphoma. | Nikita Zemlyakov, N.I. Pirogov Russian National Research Medical University, Moscow, Russia |
| 10:20-10:35 | Features of HIV-associated diffuse large B-cell lymphoma and its treatment | Anastasia Galitsyna, A. Tsyba Medical Radiological Research Centre, Russia |
| 10:35-10:50 | Outcome of patients with T-cell/histiocyte-rich large B-cell lymphoma: A single institution series | Mohammed Alshehri, King Fahad Specialist Hospital, Dammam, Saudi Arabia |
| 10:50-10:55 | Discussion | |
| 10:55-11:10 | Break | |
| 11:10-12:30 | LYMPHOPROLIFERATIVE DISORDERS AND PLASMA CELL DISCRASIAS (PART 2). Session Chairs: Prof. Natalia Mikhailova, Prof. Elena Baryakh, Prof. Gayane Tumyan | |
| 11:10-11:25 | Active surveillance is a valid option for newly diagnosed nodular lymphocyte -predominant Hodgkin Lymphoma. | Reem Abdulla, King Fahad Specialist Hospital, Dammam, Saudi Arabia |
| 11:25-11:40 | A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis | Ruichi Li, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China |
| 11:40-11:55 | First experience with the R/G-BAC regimen for the treatment of patients with early relapsed or refractory follicular lymphoma | Vladimir Murzo, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia |
| 11:55-12:10 | Residual tumor clone characteristics determined by multicolor flow cytometry and its correlation with prognosis in Waldenström's macroglobulinemia | Anastasia Vinnikova, National Medical Research Center of Hematology, Moscow, Russia |
| 12:10-12:25 | Clinical impact and prognostic implications of concurrent light-chain amyloidosis in patients with POEMS syndrome: a single-center retrospective study | Yuhan Bao, Tongji Medical College, China |
| 12:25-12:30 | Discussion | |
| 12:30-12:45 | Break | |
| 12:45-14:05 | ACUTE LEUKEMIA. Session Chairs: Prof. Vadim Ptushkin, Prof. Irina Lukyanova, Dr. Olga Alyoshina | |
| 12:45-13:00 | Association of the rs4590952 allelic variants and 12q21.32 copy-neutral loss of heterozygosity with treatment resistance in acute lymphoblastic leukemias. | Abdulpatakh Abdulpatakhov, National Medical Research Center of Hematology, Moscow, Russia |
| 13:00-13:15 | Comparison of Azacitidine--Venetoclax and Intensive Salvage Chemotherapy in Transplant-Eligible Patients with Relapsed/Refractory AML After Intensive Induction | Georgiy Pikulin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 13:15-13:30 | Venetoclax-based regimens as first-line treatment in adult patients with newly diagnosed poor cytogenetic risk AML. Single center experience | Nikita Pastukhov, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 13:30-13:45 | Comparative efficacy of ATRA-ATO induction therapy versus arsenic trioxide-free regimens in patients with acute promyelocytic leukemia | Artur Sarkisyan, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 13:45-14:00 | Diagnosis of acute lymphoblastic leukemia with CRLF2 rearrangements in children | Ivan Kotov, Ural State Medical University, Yekaterinburg, Russia |
| 14:00-14:05 | Discussion | |
| 14:05-14:35 | Break | |
| 14:35-15:55 | INNOVATIVE TECHNOLOGIES AND PRECISION APPROACHES IN HEMATOLOGY. Session Chairs: Prof. Irina Lukyanova, Prof. Yajing Zhang, Prof. Marina Popova | |
| 14:35-14:50 | A Clinical Risk Scoring System for the Prediction of Early Infection after CAR-T Therapy | An Ning, Tongji Medical College, China |
| 14:50-15:05 | Pharmacokinetic and pharmacodynamic characteristics of PGCT-002, a next-generation anti-CD19 CAR-T, in vitro and in vivo studies | Ivan Gaponenko, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 15:05-15:20 | Comparative efficacy and safety study of CCR5-Uco-hetTALEN mediated CCR5 gene knockout in CD34+ cells... | Olga Kopteva, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 15:20-15:35 | Impact of Promoter Architecture on Lentiviral Transduction Efficiency in Human CD34+ Hematopoietic Stem Cells | Valeriia Laushkina, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 15:35-15:50 | Preclinical Development of a Novel Targeted Immune Checkpoint Inhibitor for AML and MDS | Evgeniya Platonova, I.P. Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia |
| 15:50-15:55 | Discussion | |
| 15:55-16:05 | Break | |
| 16:05-17:20 | CHRONIC MYELOPROLIFERATIVE DISORDERS AND MDS. Session Chairs: Prof. Vasilyi Shuvaev, Prof. Elena Morozova, Prof. OIga Vinogradova | |
| 16:05-16:20 | Myelodysplastic Syndrome with Bone Marrow Fibrosis: Clinical and Laboratory Features and Treatment Outcomes | Iuliia Poliakova, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 16:20-16:35 | Factors influencing the achievement and duration of hematological response to lenalidomide in patients with MDS with del(5q) | Valeriya Okhota, National Medical Research Center of Hematology, Moscow, Russia |
| 16:35-16:50 | Risk stratification for survival and leukemic transformation in MDS based on TP53 mutations | Dmitrii Bug, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 16:50-17:05 | The frequency of detection of thrombophilia genes polymorphism in pregnancy complications | Nadehzda Kurkina, Mordovian State University named after N.P. Ogarev, Saransk, Russia |
| 17:05-17:20 | Clinical significance of somatic compensatory events in patients with Shwachman--Diamond syndrome | Nataliya Malyasova, Dmitry Rogachev National Medical Research Center, Moscow, Russia |
| 17:20-17:30 | Winners’ Award Ceremony | |
| 17:30-17:50 | Can we implement MOB-oriented therapy for multiple myeloma today? | Prof. Mohamad Mohty, Saint-Antoine Hospitals and Sorbonne University, Paris, France |
| 17:50-18:50 | AstraZeneca Satellite Symposium | |
| 17.50-18.05 | DLBCL: an aggressive adversary for the hematologist | L.G. Babicheva, Cand.Sc. (Medicine), RMANPO of Ministry of Health of Russia, Moscow, Russia |
| 18.05-18.20 | AL amyloidosis: the dangerous invisible threat of plasma cell dyscrasias | I.G. Rekhtina, D.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia |
| 18.20-18.35 | What? Where? When? The role and timing of CAR-T cell therapy in the treatment of adult hematologic malignancies | O.A. Alyoshina, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia |
| 18.35-18.50 | Cellular immunoadoptive therapy for multiple myeloma | Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| FEBRUARY 28th, 2026 | ||
|---|---|---|
| Timing | Title | Speakers |
| 08:00-10:20 | Plenary session: CAR-T CELL TECHNOLOGIES AND AGGRESSIVE LYMPHOMAS. Session chairs: Prof. Yajing Zhang, Prof. Vadim Ptushkin | |
| 08:00-08:20 | Modern standards of treatment for diffuse large B-cell lymphoma (DLBCL): first-line therapy | Prof. Ahmed Absi, King Abdulaziz Medical City, Jeddah, Saudi Arabia |
| 08:20-08:40 | Epcoritamab: A unified approach to the treatment of aggressive and indolent lymphoma | Prof. Gayane Tumyan, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia |
| 08:40-09:10 | CAR-T Clinical Trials and Commercial Application in Lymphoma — Current Development Status and Management in China | Prof. Yuqin Song, Beijing Cancer Hospital, China |
| 09:10-09:40 | Targeting B-lineage Cells with CAR-T: A Strategy for Lymphoid Malignancies and Autoimmune Diseases | Prof. Yajing Zhang, Beijing Gobroad Boren Hospital, China |
| 09:40-09:55 | Multiple myeloma: bridging therapy before CART and beyond | Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 09:55-10:15 | A prognostic organ-based classification and risk-stratified therapeutic framework for chronic active Epstein-Barr virus disease | Wang, Xinran, Tongji Hospital of Tongji Medical College, Wuhan, China |
| 10:15-10:20 | Discussion | |
| 10:20-10:35 | Break | |
| 10:35-12:25 | Plenary session: HEMOLYTIC ANEMIAS. Session chairs: Prof. Alexander Kulagin, Prof. Eugene Nikitin | |
| 10:35-10:50 | Treatment of PNH: the experience of Botkin Hospital | Evgeniya Arshanskaya, Cand.Sc. (Medicine), Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 10:50-11:05 | Iptacopan in real-world clinical practice. Results of the first year of PNH therapy | Prof. Kulagin Alexander, Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 11:05-11:20 | Pegcetacoplan - a step beyond traditional complement inhibition | Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 11:20-11:50 | Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) | Prof. Bruno Fattizzo, Università degli Studi di Milano, Italy |
| 11:50-12:20 | Autoimmune hemolytic anemias: state of art | Prof. Bruno Fattizzo, Università degli Studi di Milano, Italy |
| 12:20-12:25 | Discussion | |
| 12:25-13:00 | Break | |
| 13:00-14:50 | PLASMA CELL DISCRASIAS. Session chairs: Prof. Vadim Ptushkin, Prof. Raymong Wong | |
| 13:00-13:20 | From smoldering myeloma to first-line quadruplets: path to functional cure | Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 13:20-13:45 | Induction therapy with quadruplets in non-candidates for autologous HSCT: from RCTs to real-world clinical practice | Maksim Soloviev, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia |
| 13:45-14:05 | “Endless” opportunities and how to use them? What is the optimal treatment sequence? | Prof. Raymond Wong, The Chinese University of Hong Kong |
| 14:05-14:25 | Immune Breakthrough: The Role of Bispecific Antibodies Today and Their Potential for Tomorrow | Maksim Soloviev, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia |
| 14:25-14:45 | The Alchemy of Proteins and Errors of Perception: How AL Amyloidosis Eludes the Hematologist | Olga Pirogova, Cand.Sc. (Medicine), Research Institute of Children's Oncology, Hematology and Transplantology n.a. R.M. Gorbacheva, St Petersburg, Russia |
| 14:45-14:50 | Discussion | |
| 14:50-15:10 | Break | |
| 15:10-16:50 | Plenary session: ACUTE LEUKEMIA AND MYELODISPLASTIC SYNDROMES. Session chairs: Prof. Vadim Ptushkin, Dr. Olga Alyoshina | |
| 15:10-15:30 | Pegaspargase in the Treatment of Adult ALL: Russian and Global Experience | Dr. Olga Alyoshina, Cand.Sc. (Medicine), National Medical Research Center of Hematology, Moscow, Russia |
| 15:30-15:45 | Treatment of FLT3-positive AML: from induction to maintenance | Dr. Julia Kruchinkina, Cand.Sc. (Medicine), Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 15:45-16:05 | IDH1 as a Therapeutic Anchor: New Treatment Opportunities in Acute Myeloid Leukemia (AML) | Prof. Vadim Ptushkin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 16:05-16:30 | Treatment of transplant ineligible AML patients | Prof. Courtney DiNardo, MD Anderson Cancer Center, USA |
| 16:30-16:45 | Response to tyrosine kinase inhibitor therapy in patients with chronic lymphocytic leukemia | Prof. Anna Turkina, National Medical Research Center of Hematology, Moscow, Russia |
| 16:45-16:50 | Discussion | |
| 16:50-17:05 | Break | |
| 17:05-18:40 | Plenary session: CHRONIC LYMPHOCYTIC LEUKEMIA AND INDOLENT LYMPHOMAS. Session chairs: Prof. Grigory Tsaur, Prof. Eugene Nikitin, Prof. Kamil Kaplanov | |
| 17:05-18:05 | AbbVie Satellite Symposium: CORRECT AND TIMELY DIAGNOSIS AS THE KEY TO SUCCESS IN MODERN THERAPY OF PATIENTS WITH CLL | Tsaur G., D.Sc. (Medicine); Maria Ivanova, Cand.Sc. (Medicine); Maria Kislova |
| 18:05-18:20 | Modern approaches to the treatment of chronic lymphocytic leukemia: from tradition to innovation | Prof. Eugene Nikitin, Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 18:20-18:35 | First-line treatment of mantle cell lymphoma: current challenges and the role of innovative regimens | Kamil Kaplanov, D.Sc. (Medicine), Moscow Botkin Multidisciplinary Scientific-Clinical Center, Moscow, Russia |
| 18:35-18:40 | Discussion and conclusion of the conference | |
Organizers:
State Budgetary Healthcare Institution of the City of Moscow “Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin” of the Moscow City Health Department
Federal State Budgetary Educational Institution of Additional Professional Education “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of the Russian Federation
Technical Organizer:
ANO “DominantaMed”
Marksistskaya street 3 bld.1 office 3-4
Moscow 109147 Russia
Tel: +7 495 9561284
E-mail: info@dominmed.ru
© 2025 Moscow School of Hematology. All rights reserved.